Reproductive BioMedicine Online
Volume 20, Issue 2 , Pages 182-190 , February 2010

Factors related to successful ovulation induction in patients with WHO group II anovulatory infertility

  • C.M. Howles

      Affiliations

    • Merck Serono S.A. – Geneva, Switzerland an affiliate of Merck KGaA, Darmstadt, Germany
    • Corresponding Author InformationCorresponding author.
    • ,
  • V. Alam

      Affiliations

    • Merck Serono S.A. – Geneva, Switzerland an affiliate of Merck KGaA, Darmstadt, Germany
    • ,
  • D. Tredway

      Affiliations

    • EMD Serono an affiliate of Merck KGaA, Darmstadt, Germany, Global Development, Rockland, MA, USA
    • ,
  • R. Homburg

      Affiliations

    • Barzilai Medical Centre, Ashkelon, Israel
    • ,
  • D.W. Warne

      Affiliations

    • Merck Serono S.A. – Geneva, Switzerland an affiliate of Merck KGaA, Darmstadt, Germany

Received 27 April 2009 ,Revised 4 June 2009 ,Accepted 11 November 2009.

References 

  1. Aboulghar MA, Mansour RT. Ovarian hyperstimulation syndrome: classifications and critical analysis of preventive measures. Hum. Reprod. Update. 2003;9:275–289
  2. Aboulghar MA, Mansour RT, Serour GI, et al. Recombinant follicle-stimulating hormone in the treatment of patients with history of severe ovarian hyperstimulation syndrome. Fertil. Steril. 1996;66:757–760
  3. Anon, 1995. A Phase III, Open, Randomised, Multicentre Study to Compare the Safety and Efficacy of Recombinant Human Follicle Stimulating Hormone (GONAL-f) Administered Subcutaneous; with that of Urinary Human Follicle Stimulating Hormone (Metrodin) Given Intramuscularly to Induce Ovulation in WHO Group II Anovulatory Infertile Women. Ares-Serono Internal Report.
  4. Balen AH, Platteau P, Andersen AN, et al. The influence of body weight on response to ovulation induction with gonadotrophins in 335 women with World Health Organization group II anovulatory infertility. Br. J. Obstet. Gynaecol. 2006;113:1195–1202
  5. Broekmans, F., de Ziegler, D., Howles, C., et al., 2009. The antral follicle count: practical recommendations for better standardization. Fertil. Steril., doi:10.1016/j.fertnstert.2009.04.040.
  6. Broekmans FJ, Knauff EA, Valkenburg O, et al. PCOS according to the Rotterdam consensus criteria: change in prevalence among WHO-II anovulation and association with metabolic factors. Br. J. Obstet. Gynaecol. 2006;113:1210–1217
  7. Brown JB. Pituitary control of ovarian function – concepts derived from gonadotrophin therapy. Aust. NZ J. Obstet. Gynaecol. 1978;18:46–54
  8. Clark AM, Ledger W, Galletly C, et al. Weight loss results in significant improvement in pregnancy and ovulation rates in anovulatory obese women. Hum. Reprod. 1995;10:2705–2712
  9. Coelingh Bennink HJ, Fauser BC, Out HJ. Recombinant follicle-stimulating hormone (FSH; Puregon) is more efficient than urinary FSH (Metrodin) in women with clomiphene citrate-resistant, normogonadotropic, chronic anovulation: a prospective, multicenter, assessor-blind, randomized, clinical trial. European Puregon Collaborative Anovulation Study group. Fertil. Steril. 1998;69:19–25
  10. Custers IM, Steures P, van der Steeg JW, et al. External validation of a prediction model for an ongoing pregnancy after intrauterine insemination. Fertil. Steril. 2007;88:425–431
  11. Dale O, Tanbo T, Lunde O, et al. Ovulation induction with low-dose follicle-stimulating hormone in women with the polycystic ovary syndrome. Acta Obstet. Gynecol. Scand. 1993;72:43–46
  12. Delvigne A, Rozenberg S. Epidemiology and prevention of ovarian hyperstimulation syndrome (OHSS): a review. Hum. Reprod. Update. 2002;8:559–577
  13. Despres JP, Lemieux I, Prud’homme D. Treatment of obesity: need to focus on high risk abdominally obese patients. Br. Med. J. 2001;322:716–720
  14. Fauser BC, Van Heusden AM. Manipulation of human ovarian function: physiological concepts and clinical consequences. Endocr. Rev. 1997;18:71–106
  15. Gjonnaess H. Ovarian electrocautery in the treatment of women with polycystic ovary syndrome (PCOS). Factors affecting the results. Acta Obstet. Gynecol. Scand. 1994;73:407–412
  16. Gleicher N, Oleske DM, Tur-Kaspa I, et al. Reducing the risk of high-order multiple pregnancy after ovarian stimulation with gonadotropins. N. Engl. J. Med. 2000;343:2–7
  17. Hamilton-Fairley D, Franks S. Common problems in induction of ovulation. Baillière’s Clin. Obstet. Gynaecol. 1990;4:609–625
  18. Hedon B, Hugues JN, Emperaire JC, et al. A comparative prospective study of a chronic low dose versus a conventional ovulation stimulation regimen using recombinant human follicle stimulating hormone in anovulatory infertile women. Hum. Reprod. 1998;13:2688–2692
  19. Homburg R. Clomiphene citrate – end of an era? A mini-review. Hum. Reprod. 2005;20:2043–2051
  20. Homburg R, Howles CM. Low-dose FSH therapy for anovulatory infertility associated with polycystic ovary syndrome: rationale, results, reflections and refinements. Hum. Reprod. Update. 1999;5:493–499
  21. Homburg R, Insler V. Ovulation induction in perspective. Hum. Reprod. Update. 2002;8:449–462
  22. Homburg R, Levy T, Ben-Rafael Z. A comparative prospective study of conventional regimen with chronic low-dose administration of follicle-stimulating hormone for anovulation associated with polycystic ovary syndrome. Fertil. Steril. 1995;63:729–733
  23. Howles CM, Saunders H, Alam V, et al. Predictive factors and a corresponding treatment algorithm for controlled ovarian stimulation in patients treated with recombinant human follicle stimulating hormone (follitropin alfa) during assisted reproduction technology (ART) procedures. An analysis of 1378 patients. Curr. Med. Res. Opin. 2006;22:907–918
  24. Hugues JN, Cedrin-Durnerin I, Howles CM, et al. The use of a decremental dose regimen in patients treated with a chronic low-dose step-up protocol for WHO group II anovulation: a prospective randomized multicentre study. Hum. Reprod. 2006;21:2817–2822
  25. Imani B, Eijkemans MJ, Faessen GH, et al. Prediction of the individual follicle-stimulating hormone threshold for gonadotropin induction of ovulation in normogonadotropic anovulatory infertility: an approach to increase safety and efficiency. Fertil. Steril. 2002;77:83–90
  26. Imani B, Eijkemans MJ, te Velde ER, et al. Predictors of patients remaining anovulatory during clomiphene citrate induction of ovulation in normogonadotropic oligoamenorrheic infertility. J. Clin. Endocrinol. Metab. 1998;83:2361–2365
  27. Imani B, Eijkemans MJ, te Velde ER, et al. Predictors of chances to conceive in ovulatory patients during clomiphene citrate induction of ovulation in normogonadotropic oligoamenorrheic infertility. J. Clin. Endocrinol. Metab. 1999;84:1617–1622
  28. Kiddy DS, Hamilton-Fairley D, Bush A, et al. Improvement in endocrine and ovarian function during dietary treatment of obese women with polycystic ovary syndrome. Clin. Endocrinol. 1992;36:105–111
  29. Laven JS, Imani B, Eijkemans MJ, et al. New approach to polycystic ovary syndrome and other forms of anovulatory infertility. Obstet. Gynecol. Surv. 2002;57:755–767
  30. le Cotonnec JY, Porchet HC, Beltrami V, et al. Clinical pharmacology of recombinant human follicle-stimulating hormone. II. Single doses and steady state pharmacokinetics. Fertil. Steril. 1994;61:679–686
  31. Matalliotakis I, Cakmak H, Sakkas D, et al. Impact of body mass index on IVF and ICSI outcome: a retrospective study. Reprod. Biomed. Online. 2008;16:778–783
  32. Mulders AG, Laven JS, Eijkemans MJ, et al. Patient predictors for outcome of gonadotrophin ovulation induction in women with normogonadotrophic anovulatory infertility: a meta-analysis. Hum. Reprod. Update. 2003;9:429–449
  33. Olivennes F, Borini A, Germond M, et al. Optimising ovarian stimulation in ART using a novel FSH dose algorithm and follitropin alpha filled by mass: results of the CONSORT multinational study. Hum. Reprod. 2007;22:i4
  34. Olivennes F, Howles CM, Borini A, et al. Individualizing FSH dose for assisted reproduction using a novel algorithm: the CONSORT study. Reprod. Biomed. Online. 2009;18:195–204
  35. Pasquali R, Pelusi C, Genghini S, et al. Obesity and reproductive disorders in women. Hum. Reprod. Update. 2003;9:359–372
  36. Polson DW, Mason HD, Kiddy DS, et al. Low-dose follicle-stimulating hormone in the treatment of polycystic ovary syndrome: a comparison of pulsatile subcutaneous with daily intramuscular therapy. Br. J. Obstet. Gynaecol. 1989;96:746–748
  37. Polson DW, Mason HD, Saldahna MB, et al. Ovulation of a single dominant follicle during treatment with low-dose pulsatile follicle stimulating hormone in women with polycystic ovary syndrome. Clin. Endocrinol. 1987;26:205–212
  38. Popovic-Todorovic B, Loft A, Lindhard A, et al. A prospective study of predictive factors of ovarian response in ‘standard’ IVF/ICSI patients treated with recombinant FSH. A suggestion for a recombinant FSH dosage normogram. Hum. Reprod. 2003;18:781–787
  39. Scheele F, Hompes PG, van der Meer M, et al. The effects of a gonadotrophin-releasing hormone agonist on treatment with low dose follicle stimulating hormone in polycystic ovary syndrome. Hum. Reprod. 1993;8:699–704
  40. Schoemaker J, van Weissenbruch MM, Scheele F, et al. The FSH threshold concept in clinical ovulation induction. Baillière’s Clin. Obstet. Gynaecol. 1993;7:297–308
  41. Seibel MM, Kamrava MM, McArdle C, et al. Treatment of polycystic ovary disease with chronic low-dose follicle stimulating hormone: biochemical changes and ultrasound correlation. Int. J. Fertil. 1984;29:39–43
  42. Shoham Z, Patel A, Jacobs HS. Polycystic ovarian syndrome: safety and effectiveness of stepwise and low-dose administration of purified follicle-stimulating hormone. Fertil. Steril. 1991;55:1051–1056
  43. Rotterdam ESHRE/ASRM-Sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum. Reprod. 2004;19:41–47
  44. The Thessaloniki ESHRE/ASRM-Sponsored PCOS Consensus Workshop group. Consensus on infertility treatment related to polycystic ovary syndrome. Hum. Reprod. 2008;23:462–477
  45. van Santbrink EJ, Fauser BC. Urinary follicle-stimulating hormone for normogonadotropic clomiphene-resistant anovulatory infertility: prospective, randomized comparison between low dose step-up and step-down dose regimens. J. Clin. Endocrinol. Metab. 1997;82:3597–3602
  46. van Santbrink EJ, Fauser BC. Is there a future for ovulation induction in the current era of assisted reproduction?. Hum. Reprod. 2003;18:2499–2502
  47. van Santbrink EJ, Fauser BC. Ovulation induction in normogonadotropic anovulation (PCOS). Best Pract. Res. Clin. Endocrinol. Metab. 2006;20:261–270
  48. van Wely M, Fauser BC, Laven JS, et al. Validation of a prediction model for the follicle-stimulating hormone response dose in women with polycystic ovary syndrome. Fertil. Steril. 2006;86:1710–1715
  49. Wang CF, Gemzell C. The use of human gonadotropins for the induction of ovulation in women with polycystic ovarian disease. Fertil. Steril. 1980;33:479–486
  50. White DM, Polson DW, Kiddy D, et al. Induction of ovulation with low-dose gonadotropins in polycystic ovary syndrome: an analysis of 109 pregnancies in 225 women. J. Clin. Endocrinol. Metab. 1996;81:3821–3824
  51. Yeko T, Pasqualini SR, Alam V, et al. Cumulative ovulation and pregnancy rates according to recombinant human follicle stimulating hormone (r-hFSH) dosing: comparison of a new formulation of follitropin alfa in vial versus the standard formulation of follitropin alpha in ampules. Fertil. Steril. 2004;82:s119

 Dr Howles is Head of Medical Affairs Fertility, Europe, for Merck Serono S.A. – Geneva, Switzerland. Previously, he worked in clinical development, and spent almost 3years in the Far East. During the 1980s and 1990s he was involved in the development of the first highly purified recombinant FSH (follitropin alfa), human LH, human chorionic gonadotrophin and the gonadotropin-releasing hormone antagonist, cetrorelix. Dr Howles is the author or editor of more than 50 publications on reproductive endocrinology and two textbooks on reproductive medicine. His current research focuses on identifying patient characteristics as prognostic factors of ovarian response following FSH stimulation in ovulation induction and assisted reproduction treatment cycles.

PII: S1472-6483(09)00230-2

doi: 10.1016/j.rbmo.2009.11.017

Reproductive BioMedicine Online
Volume 20, Issue 2 , Pages 182-190 , February 2010

Article Tools

* Image Usage & Resolution